# Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

- Source: PR Newswire
- Published: 2026-10-25T11:01:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/final-os-analysis-results-from-phase-iii-optitrop-lung04-study-of-sacituzumab-tirumotecan-sac-tmt-presented-at-2026-esmo-302918760.html
- Canonical: https://groundlevelnews.com/story/final-os-analysis-results-from-phase-iii-optitrop-lung04-study-of-saci-5b5f6a/

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89; one-sided P = 0.0021). The 2-year OS rate was 54.1% vs 37.2%, an improvement of 16.9%; with a median...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._